

1 **COVID-19 presenting as anosmia and dysgeusia in New York City emergency**
2 **departments, March - April, 2020**

3
4 Tina Z. Wang, MD, MS¹, Jessica Sell, MPH², Don Weiss, MD, MPH², Ramona Lall,
5 PhD²

6

7 **Affiliations:**

8 1. Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine,
9 New York, NY

10 2. New York City Department of Health and Mental Hygiene, New York, NY

11

12 **Corresponding Author:**

13 Don Weiss, MD, MPH

14 Bureau of Communicable Disease

15 New York City Department of Health and Mental Hygiene

16 Gotham Center, CN# 22a

17 42-09 28th Street, 6th Floor

18 Queens, New York 11101-4132

19 (347) 396-2626

20 DWeiss@health.nyc.gov

21 **Abstract**

22 **Background:** Increasing evidence has been emerging of anosmia and dysgeusia as
23 frequently reported symptoms in COVID-19. Improving our understanding of these
24 presenting symptoms may facilitate the prompt recognition of the disease in emergency
25 departments and prevent further transmission.

26 **Methods:** We examined a cross-sectional cohort using New York City emergency
27 department syndromic surveillance data for March and April 2020. Emergency
28 department visits for anosmia and/or dysgeusia were identified and subsequently
29 matched to the Electronic Clinical Laboratory Reporting System to determine testing
30 results for SARS-CoV-2.

31 **Results:** Of the 683 patients with anosmia and/or dysgeusia included, SARS-CoV-2
32 testing was performed for 232 (34%) and 168 (72%) were found to be positive. Median
33 age of all patients presenting with anosmia and/or dysgeusia symptoms was 38, and 54%
34 were female. Anosmia and/or dysgeusia was the sole complaint of 158 (23%) patients,
35 of whom 35 were tested for SARS-CoV-2 and 23 (66%) were positive. While the
36 remaining patients presented with at least one other symptom, nearly half of all patients
37 (n=334, 49%) and more than a third of those who tested positive (n=62, 37%) did not
38 have any of the CDC-established symptoms used for screening of COVID-19 such as
39 fever, cough, shortness of breath, or sore throat.

40 **Conclusions and Relevance:** Anosmia and/or dysgeusia have been frequent
41 complaints among patients presenting to emergency departments during the COVID-19
42 pandemic, and, while only a small proportion of patients ultimately underwent testing for

43 SARS-CoV-19, the majority of patients tested have been positive. Anosmia and
44 dysgeusia likely represent underrecognized symptoms of COVID-19 but may have
45 important future implications in disease diagnosis and surveillance.

46 **Introduction:**

47 In March 2020, new anecdotal evidence emerged of anosmia and dysgeusia as
48 important clinical features of COVID-19 infection. A letter by Dr. Claire Hopkins,
49 president of the British Rhinological Society, to ENT UK described patients presenting
50 with anosmia and/or dysgeusia early in the course of COVID-19 infection and
51 occasionally in the absence of respiratory symptoms [1]. These findings have
52 subsequently been reported by researchers in several countries. In a review of
53 neurological manifestations of COVID-19 in China, 12 of 214 (5.6%) patients reported
54 hypogeusia and 11 (5.1%) reported hyposmia [2]. A retrospective survey in Italy found
55 20 of 59 (33.9%) hospitalized COVID-19 patients reported olfactory or taste dysfunction
56 and 11 (18.6%) reported both [3]. Similar reports have also been published from France,
57 Iran, and South Korea [4,5,6].

58
59 These accruing findings have prompted experts and medical societies to propose
60 screening and testing of individuals with anosmia and/or dysgeusia [7]. In response, the
61 American Academy of Otolaryngology-Head and Neck Surgery has collected and
62 analyzed 237 cases of anosmia and/or dysgeusia from around the world. The majority
63 (73%) of patients reported anosmia onset prior to COVID-19 diagnosis and 27%
64 reported no other symptoms [6]. A New York Times article published March 22, 2020
65 brought further attention to this issue [8]. In late April 2020, the Centers for Disease
66 Control and Prevention (CDC) added “new loss of taste or smell” to the symptoms to
67 watch for in COVID-19 [9].

68

69 New York City (NYC) has been the epicenter of the COVID-19 pandemic in the United
70 States. Rapid recognition and triage of cases in emergency departments (EDs) is
71 crucial to the control of the outbreak. In order to establish the role of anosmia and
72 dysgeusia in the identification of COVID-19, we reviewed the prevalence of these chief
73 complaints in ED visits and results of testing for SARS-CoV-2.

74

75 **Data and Methods:**

76 NYC's Department of Health and Mental Hygiene (DOHMH) receives ED syndromic
77 surveillance data from all 53 acute care hospital EDs in NYC. By conducting word
78 analysis of chief complaints, we are able to detect new or increasing mentions of
79 individual words. On March 15, 2020, we detected increased mentions of the words
80 "taste" and "smell."

81

82 We analyzed ED data for March and April 2020. Cases were identified by searching
83 chief complaints for mentions of "anosmia", "ageusia", "loss
84 of/no/decreased/disturbance/difficulty/unable to taste or smell" utilizing perl regular
85 expressions in R to account for misspellings and differences in sentence
86 structure. Cases were also identified by searching International Classification of
87 Diseases, 10th Revision (ICD-10) discharge diagnosis codes for R43 "Disturbances of
88 Smell and Taste."

89

90 To determine whether identified cases underwent SARS-CoV-2 PCR testing and the
91 testing result, we matched cases to the Electronic Clinical Laboratory Reporting System

92 (ECLRS) by using patient name, date of birth, and sex. Definitive name-based matching
93 was performed for 376 (55%) cases. For cases where patient name was unavailable,
94 matching was done using patient date of birth, sex, and ZIP code of residence along
95 with laboratory specimen collection ± 7 days from the ED visit date. The latter method
96 was successful in matching cases with an error rate of 8%.

97
98 Data compilations, descriptive statistics, and visualizations were conducted using R.
99 The study was evaluated by the NYC DOHMH Institutional Review Board and deemed
100 to be exempt as public health surveillance.

101

102 **Results:**

103 A total of 715 patients presented to NYC EDs in March and April 2020 with a complaint
104 of anosmia and/or dysgeusia. Of these, 683 from 47 hospitals were NYC residents and
105 were included in our analysis. For comparison, there was an average of 22 visits for
106 anosmia and/or dysgeusia in March and April of the previous 5 years (2015 through
107 2019). Visits for anosmia and/or dysgeusia increased following the publication of Dr.
108 Hopkin's letter and the New York Times article (**Figure 1**), with the majority (72%) of all
109 visits occurring between March 22 and April 11, 2020.

110

111 **Figure 1. Daily NYC ED Visits for Anosmia and/or Dysgeusia Stratified by Testing.**

112

113 Of the 683 patients, we identified SARS-CoV-2 results for 232 (34%) and 168 (72%)
114 were confirmed positive. This represents 0.1% of the 175,316 positive SARS-CoV-2

115 tests in March and April 2020. Demographic and clinical characteristic are summarized
 116 in **Table 1**. Median age of all patients was 38 years with the majority under the age of
 117 45 (425, 63%). Female patients comprised a slight majority (366, 54%). Forty-three (6%)
 118 of the 683 anosmia and/or dysgeusia were admitted.

119

120 **Table 1. Demographic and Clinical Characteristics.**

Demographic and Clinical Characteristics				
	Total		COVID-19 positive	
<i>Demographics</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
Age	683	38(median)	168	44(median)
3-17	18	3%	1	1%
18-44	407	60%	85	51%
45-64	206	30%	61	36%
65-74	43	6%	19	11%
75+	9	1%	2	1%
Sex - Female	366	54%	94	56%
Borough (County)				
Bronx	150	22%	28	17%
Brooklyn	277	41%	77	46%
Manhattan	98	14%	27	16%
Queens	123	18%	26	15%
Staten Island	35	5%	10	6%
Race				

Asian	14	2%	6	4%
Black or African American	272	40%	71	42%
White	85	12%	23	14%
Other	259	38%	56	33%
Unknown	53	8%	12	7%
Ethnicity				
Hispanic	154	23%	38	23%
Non-Hispanic	362	53%	99	59%
Unknown	167	24%	10	6%
Vital Signs				
	N	Median	N	Median
Temperature	565	98.5	147	98.6
Temp \geq 100.4F	44		19	
Heart Rate	347	87	86	89.5
Tachycardia (\geq 100/min)	75		25	
Respiratory rate	375	18	90	18
Tachypnea (\geq 20/min)	105		41	
Oxygen Saturation	487	98	121	98
Hypoxemia ($<$ 95%)	27		12	
Systolic BP	401	127	93	126
Diastolic BP	404	80	94	79
Symptoms				
	N	%	N	%

No other symptoms	158	23%	23	14%
Anosmia alone	35	5%	8	5%
Dysgeusia alone	24	4%	1	1%
Both anosmia and dysgeusia	99	14%	14	8%
Other symptoms				
Cough	221	32%	68	40%
Fever	184	27%	67	40%
Shortness of Breath	142	21%	51	30%
Headache	85	12%	17	10%
Nausea, Vomiting, Diarrhea, or Abdominal Pain	77	11%	23	14%
Bodyache	75	11%	23	14%
Malaise or Fatigue	73	11%	21	13%
Chest pain	67	10%	25	15%
Sore throat	44	6%	12	7%
Nasal congestion	37	5%	9	5%
Chills	35	5%	13	8%
Dizziness or Syncope	25	4%	7	4%

121

122 One hundred and fifty-eight (23%) patients presented with anosmia or dysgeusia in the

123 absence of any other reported symptoms. Of these, 35 were tested for SARS-CoV-2

124 and 23 (66%) tested positive. Anosmia alone was seen in 35 (5%) of COVID-19 visits

125 and 8 (5%) positive cases, while dysgeusia alone was the presenting complaint in 24

126 (4%) COVID-19 visits and 1 (1%) positive case. The remaining patients reported
127 anosmia and/or dysgeusia in addition to at least one other symptom. Only 349 (51%) of
128 all patients and 106 (63%) of those who tested positive presented with one or more
129 CDC-established symptoms recommended for screening of COVID-19 disease (cough,
130 fever, shortness of breath, or sore throat) (**Figure 2**).

131

132 **Figure 2. Daily NYC ED Visits for Anosmia and/or Dysgeusia Stratified by**
133 **Presence of Other Symptoms.**

134

135 Among the 238 patients who underwent SARS-CoV-2 testing, 16 (7%) had testing
136 performed prior to presenting with anosmia and/or dysgeusia symptoms and 124 (52%)
137 received testing during the same ED visit. The remaining 98 (41%) underwent testing at
138 a subsequent healthcare encounter a median of 7 days after their initial anosmia and/or
139 dysgeusia ED visit and 56 (57%) were found to be SARS-CoV-2 positive.

140

141 **Discussion:**

142 Anosmia and dysgeusia have been uncommon complaints of persons presenting to
143 NYC EDs in previous years. Our data show that reports of these symptoms dramatically
144 increased in late March 2020 yet testing of patients with these complaints remained low.
145 While only 34% of these patients underwent testing for COVID-19, the majority (72%) of
146 those tested were positive for the infection. Of those tested, only 52% appeared to be
147 tested as part of their ED visit. It is possible that patients presenting to EDs with
148 anosmia and dysgeusia were milder cases who did not meet stricter testing criteria. Our

149 study demonstrates that among those that did get tested there was a high percentage
150 positive, suggesting anosmia and dysgeusia are reliable symptoms for COVID-19, and
151 confirming findings of prior studies. Awareness of these symptoms as potential signs of
152 COVID-19 only recently emerged with the modification of CDC's symptom list in late
153 April. With further knowledge and expanded future testing, the proportion of persons
154 with anosmia and/or dysgeusia may represent an even larger population than our study
155 was able to capture.

156
157 Our findings support previous reports that anosmia and/or dysgeusia may be a frequent
158 complaint among patients with COVID-19 and may present in the absence of other
159 symptoms [1, 3, 6]. A significant proportion presented without classic respiratory illness
160 symptoms of cough, fever, and shortness of breath, and were not tested for SARS-CoV-
161 2. As our study shows, this presentation may be especially important in younger, female
162 patients, which is in contrast to characteristics of COVID-19-infected patients in the
163 general population who are older and predominantly male [10].

164
165 Some experts have projected that COVID-19 may eventually assume a seasonal
166 pattern of outbreaks similar to influenza. If a future resurgence of COVID-19 occurs
167 during influenza season, discrimination of the two infections may be hindered by the
168 commonality between their presenting symptoms. Anosmia and dysgeusia, which some
169 propose to be caused by direct damage to olfactory and gustatory receptors by SARS-
170 CoV-2, may be key in distinguishing COVID-19 from other influenza-like illnesses in ED

171 settings [6,11]. Furthermore, the tracking of anosmia and dysgeusia complaints may
172 play an important role in alerting public health agencies to impending outbreaks.

173
174 Our study was limited by its nature as a surveillance study. The data collected on
175 symptoms were drawn from ED medical records rather than patient interview and may
176 not reflect all of a patient's complaints. Six hospitals did not contribute any patients. This
177 could either represent a lack of COVID-19 suspect cases at these hospitals or failure of
178 the syndrome definition to capture them. Additionally, patient name for matching to
179 laboratory records was only available for 55% of our cases. The remaining cases
180 utilized other demographic data to match to SARS-CoV-2 test results in ECLRS, which
181 likely led to a small number of mismatches. Lastly, shortages in testing availability and
182 strict testing criteria throughout NYC in March and April of 2020 likely limited the ability
183 to determine the true number of SARS-CoV-2 positive cases.

184
185 To date, understanding of the pathogenesis, prevalence, and importance of these
186 symptoms remain incomplete. As our knowledge of COVID-19 evolves, we hope that
187 findings from this study will improve our understanding of the significance of non-
188 respiratory symptoms in COVID-19 and help to inform public health decisions.

189 **References:**

190

191 1. Hopkins C. Available at:

192 <https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf>. Accessed April 27.

194 2. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients
195 With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* **2020**.

196 3. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders
197 in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis* **2020**.

198 4. Klopfenstein T, Kadiane-Oussou NJ, Toko L, et al. Features of anosmia in
199 COVID-19. *Med Mal Infect* **2020**.


200 5. Bagheri SHR, Asghari AM, Farhadi M, et al. Coincidence of COVID-19 epidemic
201 and olfactory dysfunction outbreak. *medRxiv* **2020**: 2020.03.23.20041889.

202 6. Kaye R, Chang D, Kazahaya K, Brereton J, Denny J. COVID-19 Anosmia
203 Reporting Tool: Initial Findings Otolaryngology-Head and Neck Surgery **2020**.


204 7. American Academy of Otolaryngology-Head and Neck Surgery. Coronavirus
205 Disease 2019: Resources. Available at:
206 <https://www.entnet.org/content/coronavirus-disease-2019-resources>. Accessed
207 April 27.

208 8. Rabin RC. Lost Sense of Smell May be Peculiar Clue to Coronavirus Infection.
209 *New York Times*. **2020** March 22, 2020.


- 210 9. Center for Disease Control and Prevention. Symptoms of Coronavirus. Available
211 at: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.
212 Accessed April 27.
- 213 10. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
214 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19
215 in the New York City Area. *JAMA* **2020**.
- 216 11. Temmel AF, Quint C, Schickinger-Fischer B, Klimek L, Stoller E, Hummel T.
217 Characteristics of olfactory disorders in relation to major causes of olfactory loss.
218 *Arch Otolaryngol Head Neck Surg* **2002**; 128(6): 635-41.



A All Patients



B COVID-19 Positive Patients



■ Without fever, cough, shortness of breath, or sore throat
 ■ With fever, cough, shortness of breath, or sore throat